Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
World Neurosurg ; 166: 141-152, 2022 10.
Article in English | MEDLINE | ID: mdl-35843575

ABSTRACT

BACKGROUND: The role of tranexamic acid (TXA) in controlling blood loss during spine surgery remains unclear. With the publication of new randomized controlled trials (RCTs), we conducted a meta-analysis to determine the safety and efficacy of TXA in spine surgery. METHODS: PubMed, Embase, Web of Science, and Cochrane databases were searched for relevant studies through 2022. Only RCTs were eligible for this study. The extracted data were analyzed using RevMan 5.3 software for meta-analysis. RESULTS: Twenty RCTs including 1497 patients undergoing spine surgery were included in this systematic evaluation. Compared with the control group, TXA significantly reduced total blood loss (mean difference [MD] = - 218.96, 95% confidence interval [CI] = - 309.77 to - 128.14, P < 0.00001), perioperative blood loss (MD = - 90.54, 95% CI = - 139.33 to - 41.75, P = 0.0003), postoperative drainage (MD = - 102.60, 95% CI = - 139.51 to - 65.70, P < 0.00001),reduced hospital stay (MD = - 1.42, 95% CI = - 2.71 to - 0.14, P = 0.03), reduced total blood transfusion volume (MD = - 551.06, 95% CI = - 755.90 to - 346.22, P < 0.00001), and international normalized ratio (MD = -0.03, 95% CI = -0.04 to -0.02, P < 0.00001). CONCLUSIONS: Based on the meta-analysis of 20 RCTs, we demonstrated that TXA reduces blood loss in open spine surgery, decreases transfusion rates, and shortens hospital stays. The TXA administration during the perioperative period does not increase the incidence of postoperative complications.


Subject(s)
Antifibrinolytic Agents , Spinal Dysraphism , Tranexamic Acid , Antifibrinolytic Agents/therapeutic use , Blood Loss, Surgical/prevention & control , Humans , Randomized Controlled Trials as Topic , Tranexamic Acid/therapeutic use
2.
Mitochondrial DNA B Resour ; 6(12): 3506-3507, 2021.
Article in English | MEDLINE | ID: mdl-34869893

ABSTRACT

Tradescantia ohiensis Raf. (Ohio spiderwort/blue-jacket) is a perennial herb native to North America that has become widely established in China. The chloroplast (cp) genome of T. ohiensis was assembled using Illumina sequencing reads. It is 164,140 bp in length with an A + T-biased nucleotide composition, and comprises a large single-copy (LSC) region (91,248 bp), a small single-copy (SSC) region (18,426 bp), and a pair of inverted repeat (IR) regions (27,233 bp). The cp genome harbors a total of 112 gene species with 19 of them being completely or partially duplicated and 18 of them possessing one or two introns. Phylogenetic analysis suggests that T. ohiensis is most closely related to the congeneric T. virginiana.

3.
J Clin Pharm Ther ; 44(2): 157-162, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30548302

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Aristolochic acid (AA) is an abundant compound in Aristolochia plants and various natural herbs. In the 1990s, a slimming formula used in Belgium that contains Aristolochia fangchi was reported to cause kidney damage and bladder cancer, and aristolochic acid nephropathy (AAN) is now well recognized worldwide. In October 2017, researchers reported an AA signature that is closely associated with hepatocellular carcinoma (HCC) worldwide. COMMENT: There are differing opinions on the toxicity of AA, and different countries have taken different measures to address the issue. There is a lack of clarity on the causal role of AA in hepatocarcinogenesis and on the potential underlying mechanisms for the reported nephrotoxicity and carcinogenicity. The toxicity of AA differs depending on gender and age, and other risk factors that could explain the variability in the toxicity of AA remain to be identified. WHAT IS NEW AND CONCLUSION: Whether preparations containing AA, such as many Chinese medicines, should be used remains controversial, and this issue warrants further investigation before definite conclusions can be drawn.


Subject(s)
Aristolochic Acids/adverse effects , Carcinoma, Hepatocellular/chemically induced , Kidney Diseases/chemically induced , Liver Neoplasms/chemically induced , Age Factors , Aristolochic Acids/administration & dosage , Carcinoma, Hepatocellular/epidemiology , Female , Humans , Kidney Diseases/epidemiology , Liver Neoplasms/epidemiology , Male , Risk Factors , Sex Factors
4.
Biomacromolecules ; 15(11): 4260-71, 2014 Nov 10.
Article in English | MEDLINE | ID: mdl-25287757

ABSTRACT

A fully biobased and supertough thermoplastic vulcanizate (TPV) consisting of polylactide (PLA) and a biobased vulcanized unsaturated aliphatic polyester elastomer (UPE) was fabricated via peroxide-induced dynamic vulcanization. Interfacial compatibilization between PLA and UPE took place during dynamic vulcanization, which was confirmed by gel measurement and NMR analysis. After vulcanization, the TPV exhibited a quasi cocontinuous morphology with vulcanized UPE compactly dispersed in PLA matrix, which was different from the pristine PLA/UPE blend, exhibiting typically phase-separated morphology with unvulcanized UPE droplets discretely dispersed in matrix. The TPV showed significantly improved tensile and impact toughness with values up to about 99.3 MJ/m(3) and 586.6 J/m, respectively, compared to those of 3.2 MJ/m(3) and 16.8 J/m for neat PLA, respectively. The toughening mechanisms under tensile and impact tests were investigated and deduced as massive shear yielding of the PLA matrix triggered by internal cavitation of VUPE. The fully biobased supertough PLA vulcanizate could serve as a promising alternative to traditional commodity plastics.


Subject(s)
Biocompatible Materials/chemistry , Biodegradable Plastics/chemistry , Peroxides/chemistry , Polyesters/chemistry , Elastomers/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...